PL169481B1 - Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL - Google Patents

Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL

Info

Publication number
PL169481B1
PL169481B1 PL91297299A PL29729991A PL169481B1 PL 169481 B1 PL169481 B1 PL 169481B1 PL 91297299 A PL91297299 A PL 91297299A PL 29729991 A PL29729991 A PL 29729991A PL 169481 B1 PL169481 B1 PL 169481B1
Authority
PL
Poland
Prior art keywords
formula
compounds
phenylmethyl
aryl
compound
Prior art date
Application number
PL91297299A
Other languages
English (en)
Polish (pl)
Other versions
PL297299A1 (https=
Inventor
Bernard R Neustadt
Neil A Lindo
Kittrick Brian A Mc
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PL297299A1 publication Critical patent/PL297299A1/xx
Publication of PL169481B1 publication Critical patent/PL169481B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Filtering Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
PL91297299A 1990-06-21 1991-06-20 Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL PL169481B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21
PCT/US1991/004154 WO1991019717A1 (en) 1990-06-21 1991-06-20 Polycyclic guanine derivatives

Publications (2)

Publication Number Publication Date
PL297299A1 PL297299A1 (https=) 1992-07-13
PL169481B1 true PL169481B1 (pl) 1996-07-31

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
PL91297299A PL169481B1 (pl) 1990-06-21 1991-06-20 Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL

Country Status (21)

Country Link
US (1) US5393755A (https=)
EP (1) EP0538332B1 (https=)
JP (1) JPH0747589B2 (https=)
KR (1) KR960004532B1 (https=)
AT (1) ATE155786T1 (https=)
AU (1) AU651607B2 (https=)
CA (1) CA2085733C (https=)
CZ (1) CZ281920B6 (https=)
DE (1) DE69126980T2 (https=)
FI (1) FI925731A0 (https=)
HU (1) HUT65623A (https=)
IE (1) IE912126A1 (https=)
IL (1) IL98559A0 (https=)
NO (1) NO924940D0 (https=)
NZ (1) NZ238609A (https=)
OA (1) OA09723A (https=)
PL (1) PL169481B1 (https=)
RU (1) RU2080322C1 (https=)
TW (1) TW197441B (https=)
WO (1) WO1991019717A1 (https=)
ZA (1) ZA914727B (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019351A1 (en) * 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
ZA969888B (en) * 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
WO2003020724A1 (en) * 2001-08-28 2003-03-13 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
WO2003101992A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
CA2533715A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
EP1650206A4 (en) * 2003-08-01 2006-12-20 Nippon Soda Co PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
US8273750B2 (en) * 2005-06-06 2012-09-25 Takeda Pharmaceutical Company Limited Organic compounds
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
KR101388688B1 (ko) * 2005-11-09 2014-04-24 토소가부시키가이샤 퍼플루오로알킬기를 가진 핵산 염기 및 그 제조방법
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2010509399A (ja) * 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
US8349858B2 (en) * 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
AU2008335811B2 (en) 2007-12-06 2012-05-17 Intra-Cellular Therapies, Inc. Organic compounds
ES2588238T3 (es) * 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
MX2011005936A (es) * 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
CA2906640C (en) 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
WO2018049417A1 (en) 2016-09-12 2018-03-15 Intra-Cellular Therapies, Inc. Novel uses
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
AU623755B2 (en) * 1989-03-29 1992-05-21 Merrell Pharmaceuticals Inc. Selective adenosine receptor compounds
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.

Also Published As

Publication number Publication date
DE69126980D1 (de) 1997-09-04
IE912126A1 (en) 1992-01-01
HU9204032D0 (en) 1993-03-29
NO924940L (no) 1992-12-18
IL98559A0 (en) 1992-07-15
HUT65623A (en) 1994-07-28
CA2085733A1 (en) 1991-12-22
CZ281920B6 (cs) 1997-04-16
CA2085733C (en) 1996-03-05
OA09723A (en) 1993-08-30
AU651607B2 (en) 1994-07-28
WO1991019717A1 (en) 1991-12-26
US5393755A (en) 1995-02-28
JPH0747589B2 (ja) 1995-05-24
EP0538332B1 (en) 1997-07-23
FI925731A7 (fi) 1992-12-17
CZ374992A3 (en) 1993-10-13
RU2080322C1 (ru) 1997-05-27
NZ238609A (en) 1993-12-23
KR960004532B1 (ko) 1996-04-06
JPH05508647A (ja) 1993-12-02
AU8199291A (en) 1992-01-07
EP0538332A1 (en) 1993-04-28
PL297299A1 (https=) 1992-07-13
TW197441B (https=) 1993-01-01
DE69126980T2 (de) 1998-01-08
NO924940D0 (no) 1992-12-18
ATE155786T1 (de) 1997-08-15
FI925731A0 (fi) 1992-12-17
ZA914727B (en) 1992-03-25

Similar Documents

Publication Publication Date Title
PL169481B1 (pl) Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL
US6174884B1 (en) 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives
EP2769980B1 (en) Pyrazoloquinoline derivative as pde9 inhibitors
RU2603140C2 (ru) Соединения имидазотриазинона
EP3286194B1 (en) Imidazotriazinones as pde1 inhibitors
US20030176698A1 (en) Fused purine derivatives
KR20080013886A (ko) 면역억제용 퓨린 및 이미다조피리딘 유도체
KR20010032979A (ko) Ｐｄｅ ｉｖ 억제 작용을 하는 퓨린 화합물과 그의 합성방법
EP0856003A1 (en) 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A 2a? RECEPTOR
BRPI0622030A2 (pt) Derivados de purina 7-substituída, para imunossupressão
EP2708540B1 (en) Pyrimido-diazepinone compound
US11952377B2 (en) Quinolines and azaquinolines as inhibitors of CD38
BG61728B1 (bg) 2,9-дизаместени пурин-6-они
HU194878B (en) Process for producing imidazol derivatives condensed with nitrogen-containing ring and pharmaceutical compositions containing them
TW202413379A (zh) 4-烷氧基吡咯并[2,1-f][1,2,4]三𠯤及其製備與用途
FI98461C (fi) Menetelmä terapeuttisesti käyttökelpoisten yhdisteiden valmistamiseksi
US20080108652A1 (en) Imidazo (4,5-B) pyridine-derivatives as inducible no-synthase inhibitors
KR101767260B1 (ko) 피리미도 옥사진 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
EP1888585B1 (en) Tetracyclic azapyrazinoindolines as 5-ht2 ligands
EP0884318A1 (en) Fused purine derivatives
US6458792B1 (en) Compounds
US20240124464A1 (en) Substituted fused bicyclic compound as kinase inhibitor and use thereof
WO2003043637A1 (en) 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
WO2003005969A2 (en) Tetrahydropurinones as corticotropin releasing factor
JP2003252875A (ja) 新規プリン誘導体